Aldeyra Therapeutics, a clinical-stage biotech developing treatments for rare skin and eye diseases, announced terms for its IPO on Monday. The Burlington, MA-based company plans to raise $22 million by offering 2 million shares at a price range of $10 to $12. At the midpoint of the proposed range, it would command a fully diluted market value of $71 million. Aldeyra Therapeutics, which was founded in 2004, plans to list on the NASDAQ under the symbol ALDX. Aldeyra Therapeutics initially filed confidentially on December 4, 2013 and changed its name from Aldexa Therapeutics on March 4, 2014. Aegis Capital is the sole bookrunner on the deal.
